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Introduction: Antiretroviral therapy has improved the life expectancy of patients living with HIV. However,
lipodystrophy syndrome (LD) remains prevalent, affecting mostly patients treated with ﬁrst-generation
antiretroviral drugs. This syndrome is characterized by changes in body fat distribution with or without
associated metabolic changes. Here, we studied whether clinically evaluated LD is independently asso-
ciated with chronic kidney disease (CKD) development (sustained estimated glomerular ﬁltration rate
[eGFR] < 60 ml/min per 1.73 m2) in HIV-positive patients.
Methods: We conducted a prospective cohort study (the LIPOKID Study) among all the patients from the
Swiss HIV Cohort Study (SHCS) with an eGFR >60 ml/min per 1.73 m2 upon their entry into the cohort with
more than 3 months of follow-up from January 2002 to August 2016. Cox regression models were used to
estimate the association between LD and CKD development.
Results: Among the 5384 patients included, 1341 (24.9%) developed LD during the follow-up. The mean
follow-up time was 72.3 months (SD 48.4). In total, 252 patients (4.7%) reached the primary endpoint after
a median time of 51.3 months (SD 39.9 months) from inclusion. A diagnosis of LD signiﬁcantly increased
the risk of an eGFR on univariate analysis (hazard ratio [HR] ¼ 2.72; 95% conﬁdence interval [95% CI] ¼
2.073.58; P < 0.001) and remained signiﬁcantly higher after adjustment for known HIV and non-HIV risk
factors for CKD (HR ¼ 2.37; 95% CI ¼ 1.673.36; P < 0.001). The effect of LD on CKD was not mediated
through the use of nephrotoxic antiretroviral drugs.
Conclusion: Lipodystrophy syndrome is independently associated with CKD after adjustment for previ-
ously reported risk factors.
Kidney Int Rep (2018) 3, 1089–1099; https://doi.org/10.1016/j.ekir.2018.04.014
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C hronic kidney disease (CKD) is deﬁned as analteration in kidney structure and/or function
lasting more than 3 months.1,2 The prevalence of CKD is
increasing in the general population and is a major
concern for HIV-positive patients,3 whose life expec-
tancy is reaching that of uninfected patients following
the use of combined antiretroviral therapies (ARTs).46
Thus, aging HIV-positive patients are now at risk for
metabolic diseases and have a signiﬁcantly increased
risk of developing end-stage renal disease.79 Well-
established and HIV-speciﬁc risk factors for CKD
have been identiﬁed in several epidemiological studies.
These risk factors include age, diabetes, hypertension,
hepatitis B and C co-infections, lower CD4 nadirs, and
speciﬁc ARTs.1014
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CLINICAL RESEARCH
First-generation ARTs are associated with multiple
side effects. Lipodystrophy syndrome (LD) was re-
ported in 1998 by Carr et al. and is characterized by
body shape abnormalities caused by changes in body
fat distribution.15 This syndrome comprises the
following 3 phenotypes: lipohypertrophy (LH; fat
accumulation mainly in abdominal visceral adipose
tissue); lipoatrophy (LA; fat loss in the face, limbs and
buttocks); or a mixed pattern of both conditions. The
diagnosis of LD is typically made by clinical observa-
tion; however, anthropometric evaluations or objective
quantiﬁcation of fat deposition may also be per-
formed.16 These methods are not used routinely in
clinical practice given that they are not widely avail-
able, are not well normalized, and do not appear to
provide a large beneﬁt compared with that of clinical
observation or patient reporting.15,16 Given the varia-
tions in the methods used to diagnose LD, the overall
prevalence of the disease among HIV-positive patients
ranges from 28% to 60%, depending on the approach
used for its diagnosis.15,1721 The Swiss HIV Cohort
Study (SHCS) reported that although the incidence of
LD has decreased with the use of newer molecules in
patients who initiated combined ART after 2000,20 LD
remains a prevalent syndrome that has affected 33.9%
of the patients in the cohort. The mechanisms under-
lying LD development in HIV-positive patients are only
partially understood. Exposure to speciﬁc antiretroviral
drugs is likely important in the pathogenesis of LD.
However, host and/or viral factors also play an impor-
tant role in disease development.22 Clinically, LD is
associated with an elevated risk of insulin resistance
and dyslipidemia.23,24 Modiﬁcations of adipokine
secretion by abnormally deposed fat are associated with
these metabolic disturbances in HIV-positive patients.25
Evidence suggests that long-term overweight is
associated with an increased cumulative risk of CKD in
the non-HIV population.26 Speciﬁcally, an elevated
waist-to-hip ratio (WHR) in adulthood is associated with
a lower measured GFR and lower effective renal plasma
ﬂow after multiple adjustments.26 In addition, in a study
of 125 obese patients with type 2 diabetes mellitus,
WHR was independently associated with CKD.27 These
observations suggest that central fat distribution, which
is often observed in LD, is associated with GFR inde-
pendently of body mass index (BMI).
Therefore, we hypothesize that LD is independently
associated with the development of CKD as deﬁned by
an eGFR <60 ml/min per 1.73 m2. In the LIPOKID
Study, we assessed this hypothesis using data pro-
spectively collected in a large nationwide prospective
community cohort. We also analyzed the association
between LD and albuminuria in a subset of the
population.
METHODS
Study Design and Setting
The Swiss HIV Cohort Study (www.shcs.ch) is a
nationwide prospective longitudinal cohort collecting
clinical and biological data twice a year and involves
approximately 75% of all the HIV-positive adults
living in Switzerland.2830 Data are collected by 5
Swiss university hospitals, 2 tertiary care hospitals, 15
secondary care hospitals, and 36 private physicians.
The SHCS is registered on the Swiss National Science
longitudinal platform (additional information is avail-
able at http://www.shcs.ch).
The SHCS was approved by the ethics committee of
each center, and the LIPOKID study was accepted by
the scientiﬁc board of the SHCS in December 2015. The
study ﬁndings are reported according to the statement
on STrengthening the Reporting of OBservational
Studies in Epidemiology (STROBE).31
Participants and Eligibility Criteria
All HIV-positive adults who underwent creatinine
measurement upon entry into the cohort (baseline)
from January 2002 (when routine measurement of
serum creatinine began in the SHCS) to August 2016
were included in the primary analysis. Beginning in
January 2008, a urine dipstick measurement was per-
formed biannually to semiquantitatively determine
whether albuminuria was present. Patients enrolled in
this subgroup study from January 2008 to August 2016
were included in the secondary analysis. The following
patients were excluded from the study: patients with
an eGFR <60 ml/min per 1.73 m2 at baseline (ﬁrst visit
in the SHCS), patients with no follow-up creatinine
measurements, and patients who underwent <3
months of follow-up between the ﬁrst and last eGFR
values. First-semester values for each clinical and bio-
logical variable were extracted from the SHCS database
for every patient.
Outcomes
The primary outcome was CKD, which was deﬁned as
an eGFR <60 ml/min per 1.73 m2 and conﬁrmed on a
second measurement within 6 months. We used a
6-month rather than a 3-month interval to conﬁrm the
diagnosis, as patients are seen every 6 months in
the SHCS. Therefore, CKD was deﬁned according to the
second eGFR measurement. The eGFR was estimated at
baseline and at each follow-up visit using the equation
for GFR from the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI).32 We deﬁned eGFR categories
based on a CKD stage classiﬁcation (G1, $90; G2,
6089; G3, 3059; G4, 1529; and G5, <15 ml/min
per 1.73 m2).2 Beginning in 2008, dipstick testing was
used during the follow-up evaluations of the patients
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included in the SHCS, and albuminuria was diagnosed
if the dipstick (semiquantitative measure) was positive.
The diagnosis was conﬁrmed by a second measurement
within 6 months of the original measurement.
Other Variables
The main exposure variable was LD, which was diag-
nosed based on the results of a routine 6-month ques-
tionnaire by the treating physician using clinical
judgment (binary variable present/absent). LD is
characterized by “fat accumulation” (LH) and/or “fat
loss” (LA). LD, LA, and/or LH were considered present
in each patient when diagnosed on 2 consecutive visits
within a 6-month interval.
Information pertaining to other variables, namely,
sociodemographic variables (age, gender, and
ethnicity), variables speciﬁc for HIV infection (CD4
count, HIV load, hepatitis C virus (HCV) and hepatitis B
virus (HBV) co-infection, AIDS status, antiretroviral
regimens, and cumulative exposure to ART) and risk
factors for cardiovascular and renal diseases (diabetes,
high blood pressure, total cholesterol, HDL cholesterol
and triglycerides, body mass index, WHR, and smoking
status), was also collected. We deﬁned calendar times as
follows: 2002 to 2005, 2006 to 2008, and 2009 to 2016.
Study Size
From 2002 to 2016, a total of 6066 patients were
included in the SHCS, and 1781 patients (30.7%) were
diagnosed with LD during follow-up. We assumed that
25% to 28% of patients with LD would develop CKD,
15% to 18% of patients without LD would develop
CKD, and at least 5000 observations would be available.
These features provide the study with sufﬁcient power
to demonstrate a difference in the incidence of CKD
between HIV-infected patients with and without LD.
Statistical Methods
Continuous variables are presented as the mean  SD,
median, and interquartile range, and categorical vari-
ables are presented as a frequency and relative per-
centage. Incidence rates are provided with their 95%
conﬁdence intervals (95% CIs). We compared the
proportions of eGFR categories by LD phenotypes at
baseline and at the last follow-up visit using the c2 test.
We compared all the descriptive variables between
patients included in ﬁnal analyses and those who were
excluded using either the c2 test or Student t test,
depending on the types of variables.
To explore the association between LD and the
primary outcome (an eGFR <60 ml/min per 1.73 m2),
we used a Cox proportional hazards model. First, we
assessed multicollinearity among the risk factors
at baseline (among diabetes, hypertension, total
cholesterol, HDL cholesterol, and triglycerides; among
WHR, BMI, total cholesterol, HDL cholesterol, and
triglycerides) (collin command in Stata). Then we built
our multivariate model using a manual forward pro-
cedure by starting with the main predictor, LD (binary
or in categories), antiretroviral regimens (antiretroviral
exposure deﬁned by 2 categories: tenofovir and/or
protease inhibitor-based regimen (TDF/PI), and other
combinations), and cumulative exposure to TDF and/or
PI (<1 year, 12 years, 23 years and $3 years). Then,
we introduced each covariate one by one to assess their
potential confounding effects on our main association
between LD and eGFR <60 ml/min per 1.73 m2. We
also included demographic variables, HIV-related var-
iables, such as current CD4 counts (<199, 200349,
and $350/mm3), HIV load (<1000 copies/ml or $1000
copies/ml), and the presence of prior AIDS disease,
hepatitis B virus seropositivity, and hepatitis C sero-
positivity. We also tested whether an interaction
existed between TDF/PI and cumulative exposure to
ART in the multivariable model. Finally, we included
established risk factors for renal impairment, such as
hypertension, diabetes, dyslipidemia (deﬁned as total
cholesterol$6.2 mmol/l and/or HDL <0.9 mmol/l, and/
or triglycerides $2.26 mmol/l), age in years (as a
continuous variable), and baseline eGFR (as a contin-
uous variable). We included the WHR adjusted for
gender (introduced as a categorical variable below or
above the limit $0.85 in men and $0.90 in women).
For continuous variables, we veriﬁed whether they had
a log-linear hazard. All the covariates were introduced
as time varying, except for ethnicity and gender. Time
included baseline to the ﬁrst occurrence of CKD.
To test whether the association between LD and CKD
was mediated by increased use of TDF, we assessed the
combined effect of LD and TDF-based regimens (TDF/PI
use) on the risk of CKD. Accordingly, interaction effects
were identiﬁed on the additive and multiplicative
scales. Regarding the additive interaction, the relative
excess risk due to interaction was calculated.33 Finally,
we restricted the analysis to the patients who were
never treated with TDF/PI during the follow-up, and
we reassessed the association between LD and CKD in
univariate and multivariate models. For the secondary
outcome (albuminuria), we built our multivariate model
using the same approach and adjusted for the center to
account for some variations in albuminuria measure-
ment methods among the centers. Testing for non-
proportional hazards using the Schoenfeld residuals
was performed in the ﬁnal multivariate models.34
Sensitivity Analysis
We performed several sensitivity analyses. We deﬁned
an eGFR <60 ml/min based on the CKD-EPI equation
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without the race factor. We also assessed the composite
outcome of eGFR <60 ml/min per 1.73 m2 and/or
albuminuria using the same approach as that for pri-
mary and secondary outcomes.
Statistical analyses were performed using STATA IC
150 (Stata Statistical Software, Release 14.0; Stata
Corporation, College Station, TX).
RESULTS
Participants
Among the 6051 eligible participants from the SHCS,
350 (5.8%) did not have creatinine measurements at
entry. In addition, 108 (1.8%) had an eGFR <60 ml/min
per 1.73 m2 at baseline and were thus not included in
the statistical analysis. We assessed the risk of renal
dysfunction among the 5593 patients who met the
eligibility criteria. Of these patients, 209 had no data
pertaining to their LD status; thus, a total of 5,384
patients were included in the statistical analysis
(Figure 1). Patients who were excluded from the sta-
tistical analysis were older (41.3 12.5 years vs. 38.8
10.7 years, P < 0.001) and were more often receiving
ART (285 [42.7%] vs. 2735 [50.8%], P < 0.001),
particularly at baseline (235 [35.2%] vs. 1515 [28.1%],
P < 0.001) than were patients included in the statistical
analysis.
Patient Characteristics
Table 1 summarizes the baseline demographic and
clinical characteristics of the patients overall, and
characteristics between the patients who developed
CKD versus those who did not. The patient population
included in the study comprised mostly white partic-
ipants (72.6%) and mostly males (73.7%), with a mean
age of 38.8 years. No patients with LD were reported at
baseline (i.e., the time of entry into the cohort irre-
spective of previous ART administration). The mean
eGFR at baseline was 106 ml/min per 1.73 m2. Overall,
79.5% of patients had an eGFR >90 ml/min per 1.73
m2, and 20.5% had an eGFR between 60 and 90 ml/min
per 1.73 m2. At baseline, 4282 patients (79.5%) were in
the G1 eGFR category, and 1102 patients (20.5%) were
in the G2 eGFR category (Supplementary Table S1). No
patient presented with LD at entry into the study.
The mean number of visits in the SHCS was 17.9
(14.8), and the mean follow-up time was 72.3 months
(SD 48.4 months). Of the 5384 patients enrolled in the
study, 252 (4.7%) reached the primary endpoint.
6051 Patients in the SHCS with follow-
up data from Jan 1, 2002
5701 Patients with a laboratory result within 30
days of inclusion in the SHCS
350 Patients excluded (missing laboratory value 
for baseline creatinine)
5593 Patients with an 
eGFR ≥60 at baseline
108 Patients excluded
(eGFR <60 at baseline)
209 Patients with no LD
status
5384 Patients in the primary
analysis (eGFR <60)
2359 Patients included
before 1 January 2008
3025 Patients in the
secondary analysis
(albuminuria)
Figure 1. Patient inclusion ﬂow chart. eGFR, estimated glomerular ﬁltration rate; LD, lipodystrophy syndrome; SHCS, Swiss HIV Cohort Study.
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Table 1. Demographic and clinical characteristics at baseline
Variables n [ 5384
n [ 252 Patients
with CKD
n [ 5132 Patients
Without CKD P value
Socio-demographic
Mean age, yr (SD, median, min–max) 38.8 (10.7, 38, 16–80) 51.0 (12.7, 50.5, 19–80) 38.2 (10.2, 37, 16–79) <0.001
Gender, n (%) 0.595
Men 3966 (73.7) 182 (72.2) 3784 (73.7)
Women 1418 (26.3) 70 (27.8) 1348 (26.3)
Ethnicity, n (%) <0.001
White 3906 (72.6) 224 (88.9) 3682 (71.8)
Black 942 (17.5) 11 (4.4) 931 (18.2)
Hispano-American 252 (4.7) 5 (2.0) 247 (4.8)
Asian 269 (5.0) 11 (4.4) 258 (5.0)
Other 11 (0.2) 1 (0.4) 9 (0.2)
HIV infection
Mean initial CD4 count (SD, median, min–max) 388 (271, 355, 1–2851) 335 (265, 280, 3–1421) 391 (271, 358, 0–2851) 0.0014
Categories of CD4 count, cells/ml (%) 0.003
<200 1413 (26.2) 89 (35.3) 1324 (25.8)
200–349 1231 (22.9) 61 (24.2) 1170 (22.8)
350–499 1200 (22.3) 43 (17.1) 1157 (22.5)
$500 1540 (28.6) 59 (23.4) 1481 (28.9)
Mean initial RNA count, log10 (SD, median, min–max) 4.1 (1.3, 4.3, 0.3–8.7) 4.1 (1.5, 4.2, 0.8–8.1) 4.0 (1.3, 4.3, 0.3–8.7) 0.863
Categories of RNA, n (%) 0.095
<80 533 (9.9) 21 (8.4) 512 (10.0)
80–1999 459 (8.6) 17 (6.8) 442 (8.6)
2000–9999 650 (12.1) 21 (8.4) 629 (12.3)
$10,000 3728 (69.4) 191 (76.4) 3537 (69.1)
Route of HIV transmission, n (%) 0.070
MSM 2563 (47.6) 102 (40.5) 2461 (48.0)
Heterosexual 2104 (39.1) 109 (43.2) 1995 (38.9)
IDU 431 (8.0) 28 (11.1) 403 (7.9)
Blood products 35 (0.7) 3 (1.2) 32 (0.6)
Perinatal transmission 62 (1.2) 0 (0) 62 (1.2)
Unknown 144 (2.7) 8 (3.2) 136 (2.6)
Other 45 (0.8) 2 (0.8) 43 (0.8)
AIDS status, n (%) 736 (13.7) 55 (21.8) 681 (13.3) <0.001
Co-infection with HBV, n (%) 1673 (31.1) 96 (38.1) 1577 (30.7) 0.014
Co-infection with HCV, n (%) 427 (7.9) 18 (7.1) 409 (8.0) 0.635
No ART at baseline, n (%) 2739 (50.9) 118 (46.8) 2621 (51.1) 0.188
ART drugs used among patients treated, n (%)
Tenofovir 1515 (28.1) 71 (28.2) 1444 (28.1) 0.990
Ritonavir 1159 (21.5) 66 (26.2) 1093 (21.3) 0.065
Cardiovascular and other risk factors
Family history of cardiovascular disease, n (%) (n ¼ 5367) 540 (10.1) 25 (9.9) 515 (10.1) 0.994
Family history of diabetes, n (%) (n ¼ 2790) 501 (18.0) 21 (26.9) 480 (17.7) 0.112
Personal history of diabetes, n (%) 177 (3.3) 29 (11.5) 148 (2.9) <0.001
Personal history of high blood pressure, n (%) (n ¼ 5357) 329 (6.1) 47 (18.7) 282 (5.5) <0.001
Smoking habits, n (%) (n ¼ 5284) 2279 (43.1) 85 (34.8) 2194 (43.5) 0.007
i.v. Heroin use, n (%) (n ¼ 3369) 45 (1.3) 1 (0.9) 44 (1.4) 0.875
i.v. Cocaine use, n (%) (n ¼ 3369) 78 (2.3) 2 (1.8) 76 (2.3) 0.888
Cannabis consumer, n (%) (n ¼ 3368) 590 (17.5) 13 (11.7) 577 (17.7) 0.215
LD, n (%) (n ¼ 5384)
No LD 5384 (100) 252 (100) 5132 (100) —
Mean creatinine, mmol/l (SD, median, min–max) 76.1 (15.8, 76, 11–135) 86.4 (16.1, 86, 35–131) 75.6 (15.6, 76, 11–135) <0.001
Mean GFR, ml/min per 1.73 m2 (SD, median, min–max) 106 (19.3, 106, 60.2–238.4) 84.7 (18.0, 80.9, 60.3–171) 107.1 (18.7, 107, 60.2–238.4) <0.001
GFR stages, n (%) <0.001
G1 4282 (79.5) 86 (34.1) 4196 (81.8)
G2 1102 (20.5) 166 (65.9) 936 (18.2)
Albuminuria, n (%) 85 (1.6) 4 (1.6) 81 (1.6) 0.991
Mean weight, kg (SD, median, min–max) (n ¼ 4670) 71.1 (13.6, 70, 35–197) 70.7 (13.2, 71, 42–116) 71.2 (13.6, 70, 35–197) 0.6475
Mean BMI, kg/m2 (SD, median, min–max) (n ¼ 4670) 23.6 (3.8, 23.1, 14.3–74.0) 23.9 (3.8, 23.5, 16.7–41.0) 23.6 (3.8, 23.1, 14.3–74) 0.2281
(Continued on next page)
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Of the 5384 patients with data pertaining to their LD
status, 1341 (24.9%) were reported to have LD on 2
consecutive visits and at least once during the follow-
up period. The overall incidence of LD was 53.0 per
1000 patient-years (95% CI ¼ 50.255.9). It was 68.3
(95% CI ¼ 59.878.1) in 2002 to 2005, 30.2 (95% CI ¼
27.033.8) in 2006 to 2008, and 34.3 per 1000 patient-
years (95% CI ¼ 32.036.7) in 2009 to 2016. Overall,
912 patients (16.9%) developed LH, 327 (6.1%) pa-
tients developed LA, and 102 (1.9%) developed both
LA and LH. Of these patients, 1314 (98.0%) were
treated with ARTs for a mean time of 34.2 months (SD
39.2 months) until the ﬁrst report of LD. The mean time
from the ﬁrst LD report to the primary endpoint was
51.3 months (SD 39.9, median ¼ 40.4, interquartile
range ¼ 17.681.7 months). Twenty-two patients
(1.6%) reported the occurrence of LD after the devel-
opment of the primary outcome and were therefore not
included in the survival analysis
Association Between Lipodystrophy and an
eGFR <60 ml/min per 1.73 m2
Per the univariate analysis (Table 2), LD exhibited a
signiﬁcantly increased hazard ratio (HR) of 2.7 for the
development of CKD (Figure 2). The combination of
LAþLH was associated with a signiﬁcantly increased
HR of 3.5 for development of CKD. Fat loss alone was
associated with a signiﬁcantly increased HR of 3.0, and
LH alone was associated with a signiﬁcantly increased
HR of 2.6. The presence of LD was signiﬁcantly asso-
ciated with an increased HR of 2.4 for the development
of CKD via multivariable analysis after adjustment for
known CKD risk factors and prespeciﬁed confounders
(Table 2). A signiﬁcant interaction was observed be-
tween the TDF/PI-based regimen and cumulative
exposure: longer exposure to a TDF/PI-based regimen
corresponded to a higher risk of CKD. The LD pheno-
types were also signiﬁcantly associated with an
increased HR for CKD development (Supplementary
Table S2). Compared with no LD, LA alone exhibited
an increased HR of 2.3, LH alone exhibited an increased
HR of 2.1, and the combination of LA and LH exhibited
an increased HR of 2.8. Other independent risk factors
for developing CKD were low baseline eGFR, older age,
low HIV load, exposure to TDF/PI regimens, cumula-
tive exposure to ART, co-infection with HBV, diabetes,
and nonblack ethnicity.
In the sensitivity analysis, we conﬁrmed that LD was
associated with an increased risk of CKD (HR ¼ 2.39,
95% CI ¼ 1.703.36, P < 0.001 with CKD-EPI without
the race factor. The nonblack ethnicity risk was no
longer signiﬁcant in this analysis.
Regarding the interaction analysis between LD and
TDF/PI use, no evidence was observed for a multipli-
cative interaction between LD and TDF/PI use (HR ¼
1.43, P ¼ 0.295). For the additive interaction, the
relative excess risk due to interaction was positive and
signiﬁcant, suggesting that the combination of 2 haz-
ards was larger than the sum of the number of events
that would be associated with the individual risk fac-
tors separately (relative excess risk due to interaction ¼
3.18, 95% CI ¼ 0.196.18, P ¼ 0.0372). In the model
restricted to patients who had never received TDF/PI
during their follow-up (n ¼ 3196), we conﬁrmed that
LD was associated with an increased hazard of CKD in
the univariate model (HR ¼ 2.90, 95% CI ¼ 1.864.52,
Table 1. (Continued)
Variables n [ 5384
n [ 252 Patients
with CKD
n [ 5132 Patients
Without CKD P value
BMI categories, n (%) (n ¼ 4670) 0.480
BMI <18.5 kg/m2 267 (5.7) 12 (5.7) 255 (5.7)
18.5–25 3003 (64.3) 125 (59.5) 2878 (64.5)
25–30 1125 (24.1) 59 (28.1) 1066 (23.9)
$30 275 (5.9) 14 (6.7) 261 (5.9)
Mean cholesterol, mmol/l (SD, median, min–max)
(n ¼ 4988)
4.55 (1.13, 4.45, 1.50–13.80) 4.78 (1.23, 4.60, 2.40–10.8) 4.53 (1.12, 4.42, 1.50–13.80) 0.0015
Mean HDL, mmol/l (SD, median, min–max) (n ¼ 4647) 1.17 (0.44, 1.1, 0.02–5.6) 1.08 (0.41, 1.03, 0.19–3.13) 1.17 (0.44, 1.10, 0.02–5.60) 0.0031
Mean cholesterol/HDL ratio (SD, median, min–max)
(n ¼ 4641)
4.37 (2.41, 4.0, 0.70–80.0) 4.87 (1.74, 4.62, 1.75–13.53) 4.35 (2.44, 3.99, 0.70–80.0) 0.0016
Mean triglycerides, mmol/l (SD, median, min–max)
(n ¼ 4976)
1.73 (1.31, 1.40, 0.02–26.74) 2.17 (1.48, 1.85, 0.40–10.83) 1.71 (1.29, 1.37, 0.02–26.74) <0.001
Mean hip values, cm (SD, median, min–max) (n ¼ 4782) 94.6 (9.3, 94, 10–170) 95.5 (8.9, 95, 67–136) 94.5 (9.34, 94, 10–170) 0.1354
Mean waist values, cm (SD, median, min–max)
(n ¼ 4790)
84.5 (11.0, 84, 55–172) 87.1 (11.2, 87, 64–133) 84.4 (11.0, 83, 55–172) 0.0003
Mean waist–hip ratio (SD, median, min–max) (n ¼ 4781) 0.90 (0.17, 0.89, 0.58–11.7) 0.91 (0.07, 0.91, 0.76–1.11) 0.89 (0.18, 0.89, 0.58–11.7) 0.1449
In men (n ¼ 3573) 0.91 (0.19, 0.90, 0.63–11.7) 0.93 (0.07, 0.93, 0.78–1.11) 0.91 (0.20, 0.90, 0.63–11.7) 0.1622
In women (n ¼ 1208) 0.85 (0.08, 0.85, 0.58–1.45) 0.86 (0.06, 0.85, 0.76–1.02) 0.85 (0.08. 0.85, 0.58–1.45) 0.2713
ART, antiretroviral therapy; BMI, body mass index; CKD, chronic kidney disease; GFR, glomerular ﬁltration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HDL, high-density lipo-
protein; IDU, intravenous drug user; LD, lipodystrophy syndrome; MSM, men having sex with men.
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P < 0.001). The association between LD and CKD
remained signiﬁcant after adjustment for other risk
factors (HR ¼ 1.91, 95% CI ¼ 1.073.39, P ¼ 0.028).
Association Between LD and Albuminuria in
Patients Included in the Cohort After 2008
A total of 2359 patients (43.8%) were enrolled in the
SHCS before 1 January 2008, the date after which
proteinuria dipstick testing was systematically per-
formed, and thus were excluded from the subgroup
analysis regarding albuminuria (Figure 1). Among the
patients enrolled in the subgroup (n ¼ 3,025), 555
(18.3%) developed LD during follow-up. Albuminuria
occurred after a mean time of 17.1 months (14.3,
median time ¼ 16.5, interquartile range ¼ 4.822.9
months). A total of 44 patients were ﬁrst diagnosed
with LD after developing albuminuria and were thus
not included in the survival analysis. To account for
some differences among the centers regarding albu-
minuria measurement by dipstick, we adjusted sec-
ondary analyses for centers. Univariate analyses are
presented in Table 3. LD was not signiﬁcantly
Table 2. Univariate (left) and multivariable (right) associations between CKD (which is deﬁned as an eGFR <60 ml/min per 1.73 m2) and LD and
known risk factors for CKD
Variables
Univariate analysis Multivariable analysis
Hazard ratio (95% CI), P value Hazard ratio (95% CI), P value
Category of lipodystrophy (reference no LD) P < 0.001 —
Fat loss (LA) 2.96 (1.89--4.64), P < 0.001
Fat accumulation (LH) 2.57 (1.88--3.52), P < 0.001
Fat loss and accumulation (LH þ LA) 3.47 (1.62--7.44), P [ 0.001
Lipodystrophy (reference, no LD) 2.72 (2.07--3.58), P < 0.001 2.37 (1.67--3.36), P < 0.001
Baseline GFR, ml/min per 1.73 m2 0.93 (0.92--0.94), P < 0.001 0.95 (0.93--0.96), P < 0.001
HIV-associated risk factors for renal outcomes
AIDS status at baseline 1.87 (1.39--2.52), P < 0.001 0.96 (0.66–1.38), P ¼ 0.817
HIV infection route (reference, heterosexuals) P [ 0.001 —
IDU 1.58 (1.04--2.39), P [ 0.031
Men having sex with men 0.71 (0.55--0.94), P [ 0.015
Other 0.83 (0.47--1.48), P [ 0.536
CD4 count during follow-up (reference, CD4 $350/mm3) P [ 0.017 P ¼ 0.473
200–349 1.40 (1.01--1.94), P [ 0.041 1.22 (0.82–1.82), P ¼ 0.320
<199 1.63 (1.09--2.44), P [ 0.017 0.86 (0.46–1.61), P ¼ 0.642
Viremia $1000 copies/ml (reference, <1000) 0.35 (0.23--0.53), P < 0.001 0.30 (0.17--0.53), P < 0.001
Tenofovir and/or protease inhibitor–based regimen (reference, other) 2.07 (1.60--2.67), P < 0.001 —
Cumulative exposure to ART (reference, $3 year) P ¼ 0.112 —
<1 year 1.51 (1.02–2.24), P ¼ 0.042
1–2 years 0.94 (0.56–1.56), P ¼ 0.801
2–3 years 1.30 (0.93–1.83), P ¼ 0.129
Interaction between TDF/PI-based regimen and cumulative exposure to ART P ¼ 0.328 P ¼ 0.021
TDF/PI-based regimen and <1 year (ref. other ART) 2.50 (1.43--4.39), P [ 0.001 1.39 (0.84–2.31), P ¼ 0.203
TDF/PI-based regimen and 1–2 years 2.25 (0.96–5.31), P ¼ 0.063 1.36 (0.99–1.85), P ¼ 0.055
TDF/PI-based regimen and 2–3 years 1.65 (1.12--2.42), P [ 0.011 3.80 (1.46--9.92), P [ 0.006
TDF/PI-based regimen and $3 years 2.98 (1.71--5.19), P < 0.001 3.33 (1.79--6.22), P < 0.001
HBV co-infection (reference, no co-infection) 1.62 (1.27--2.08), P < 0.001 1.63 (1.19--2.23), P [ 0.002
HCV co-infection (reference, no co-infection) 1.55 (1.08--2.23), P [ 0.017 1.38 (0.87–2.20), P ¼ 0.167
Other risk factors associated with the primary outcome
Male gender 0.91 (0.69–1.20), P ¼ 0.491 0.80 (0.51–1.25), P ¼ 0.324
Age, yr (continuous variable) 1.10 (1.08--1.11), P < 0.001 1.06 (1.04--1.08), P < 0.001
Diabetes (reference, no diabetes) 4.12 (2.73--6.23), P < 0.001 1.86 (1.12--3.10), P [ 0.017
Hypertension (reference, no hypertension) 1.30 (0.80–2.13), P ¼ 0.294 0.92 (0.55–1.56), P ¼ 0.765
Nonblack ethnicity (reference, black ethnicity) 4.53 (2.48--8.30), P < 0.001 5.04 (1.79--14.19), P [ 0.002
BMI (reference BMI <18.5 kg/m2) 0.025 —
18.5–25 1.75 (1.00--3.05), P [ 0.050
25–30 1.41 (1.06--1.89), P [ 0.020
$30 1.56 (1.02--2.38), P [ 0.040
Waist–hip ratio adjusted for gender above the limit (reference <0.85 in men and <0.90 in women) 1.25 (0.93–1.67), P ¼ 0.138 0.71 (0.44–1.14), P ¼ 0.155
Dyslipidemia (reference, no dyslipidemia) 1.81 (1.35--2.43), P < 0.001
Smoker (reference, no smoking) 0.75 (0.58--0.98), P [ 0.032 0.84 (0.60–1.18), P ¼ 0.312
ART, antiretroviral therapy; BMI, body mass index; CI, conﬁdence interval; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; HBV, hepatitis B virus; HCV, hepatitis C
virus; PI, protease inhibitors; ref., reference; TDF, tenofovir.
Boldface type denotes results with a P value of <0.05.
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associated with albuminuria on univariate analysis. The
association between LD and albuminuria remained
nonsigniﬁcant after adjustment for the main CKD risk
factors (Supplementary Table S3). In the sensitivity
analysis, we conﬁrmed that LD was not signiﬁcantly
associated with the composite outcome (HR ¼ 1.17,
95% CI ¼ 0.841.63, P ¼ 0.362) after adjustment for
the main risk factors.
CONCLUSION
In this large prospective nationwide cohort including
HIV-positive patients in Switzerland, we observed that
LD was associated with the development of CKD
(deﬁned as an eGFR <60 ml/min per 1.73 m2), inde-
pendent of classic and HIV-associated CKD risk factors
such as diabetes, hypertension, cumulative exposure to
a TDF/PI-based regimen or viral load, as well as lipid
metabolism alterations and WHR modiﬁcations. Age,
co-infection with hepatitis B, and exposure to a TDF/PI-
based regimen were also independently associated with
an increased hazard ratio for an eGFR <60 ml/min per
1.73 m2. We did not identify an association between LD
and albuminuria. The association with LD was not
mediated through increased use of TDF (with or without
PI), as demonstrated in the multivariable analysis.
This is the ﬁrst study with a long follow-up and a
large, well-followed cohort to report an association
between clinically deﬁned LD and the later develop-
ment of CKD in HIV-positive patients. Metabolic and
common risk factors could not explain our observation,
and the independent risk conferred by LD is high. This
observation is of great clinical importance, as a large
fraction of HIV patients display the LD phenotype.
Therefore, our observations imply that speciﬁc kidney
surveillance should be performed in this population,
and that nephrotoxic drugs, including ARTs, should
generally be administered with caution in these pa-
tients, as the risks of CKD may be additive.
Some hypotheses may explain how LD may be
associated with the development of CKD independent
of other factors. Adipokines modulate kidney lesions
and ﬁbrosis progression.35,36 A human case-control
study revealed an association between alterations in
speciﬁc adipokines and the presence of CKD.37 There-
fore, the modiﬁcation of adipokines, which is known to
occur in LD,25,38 may underlie the observed association
between LD and the incidence of CKD.
Our study results contrast with those of the study
by Malkina et al.,39 who did not observe statistically
signiﬁcant associations between magnetic resonance
imagingmeasured regional adiposity or serum adipo-
kines and rapid kidney functional decline or incidental
CKD. However, the number of patients and the average
follow-up period of 5 years were likely too small and
too brief, respectively, to observe differences in
Figure 2. Forest plot of chronic kidney disease (CKD) by lipodys-
trophy syndrome (LD) in univariate and multivariable models.
Table 3. Univariate associations between LD and albuminuria and
known risk factors for CKD
Variables Hazard ratio (95% CI), P value
Categories of lipodystrophy (reference, no LD) P ¼ 0.366
Fat loss (LA) 0.99 (0.67–1.50), P ¼ 0.99
Fat accumulation (LH) 1.64 (0.94–2.88), P ¼ 0.081
Fat loss and accumulation (LH þ LA) 0.74 (0.10–5.26), P ¼ 0.760
Lipodystrophy (reference, no LD) 1.13 (0.81–1.59), P ¼ 0.464
HIV-associated risk factors for renal outcomes
AIDS status at baseline 1.48 (1.12--1.96), P [ 0.006
HIV infection route (reference, heterosexuals) P ¼ 0.161
IDU 1.20 (0.94–1.54), P ¼ 0.140
Male–male intercourse 1.62 (1.03--2.56), P [ 0.037
Other 1.08 (0.66–1.79), P ¼ 0.757
CD4 count during follow-up
(reference, CD4 $350/mm3)
P < 0.001
200–349 1.52 (1.16--1.99), P [ 0.002
<199 1.75 (1.25--2.43), P [ 0.001
Log10 viremia during follow-up 0.73 (0.57--0.94), P [ 0.015
Exposure to a TDF/PI-based regimen
(reference, other)
1.61 (1.39--1.88), P < 0.001
HBV co-infection (reference, no co-infection) 1.45 (1.16--1.81), P [ 0.001
HCV co-infection (reference, no co-infection) 1.35 (0.92–1.99), P ¼ 0.129
Other risk factors associated with the
primary outcome
Age 1.02 (1.01--1.03), P < 0.001
Diabetes (reference, no diabetes) 1.86 (1.07--3.24), P [ 0.029
Hypertension (reference, no hypertension) 2.11 (1.47--3.03), P < 0.001
Nonblack ethnicity (reference, black ethnicity) 0.92 (0.68–1.25), P ¼ 0.595
BMI 0.99 (0.96–1.02), P ¼ 0.394
Waist–hip ratio above limita 1.55 (1.18--2.05), P [ 0.002
Total cholesterol 1.11 (1.01--1.21), P [ 0.030
HDL cholesterol 0.76 (0.58–1.00), P ¼ 0.054
Triglycerides 1.02 (0.99–1.05), P ¼ 0.227
Smoking habits 1.28 (1.03--1.59), P [ 0.023
BMI, body mass index (continuous time-dependent variable); CI, conﬁdence interval;
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; HBV, hepatitis B
virus; HCV, hepatitis C virus; NRTI, nucleoside reverse transcriptase inhibitors; RTV,
ritonavir; TDF, tenofovir.
Boldface type denotes results with a P value of <0.05.
aAdjusted for gender.
CLINICAL RESEARCH Y Bouatou et al.: Lipodystrophy and CKD in Patients With HIV
1096 Kidney International Reports (2018) 3, 1089–1099
outcomes, as we demonstrated that the development of
an eGFR <60 ml/min occurred after a mean observation
time of 6 years.
In the present study, the association between LD
and kidney disease was restricted to eGFR and did not
affect albuminuria, which may be explained by the low
number of patients available with albuminuria mea-
surements, the low sensitivity of dipstick testing, or
the shorter follow-up in this subgroup of patients.
Also, the incidence of LD was drastically reduced in
2008 in patients with albuminuria data, which can be
explained by the fact that drugs associated with LD
such as zidovudine, stavudine, and protease inhibitors
were less prescribed from 2008. Alternatively, LD may
induce CKD by nonglomerular lesions and may there-
fore be independent of albuminuria.
Some additional observations warrant commentary.
A clear association between combined ART, including
TDF alone or in combination with a PI, and the devel-
opment of an eGFR <60 ml/min per 1.73 m2 was iden-
tiﬁed by multivariable analysis in a cumulative fashion.
This association was previously reported in a case-
control study with TDF in combination with a ritona-
vir boost, resulting in greater renal function decline
over 48 weeks, and may rely on a drugdrug interac-
tion between ritonavir and TDF.40 No association was
identiﬁed between an eGFR<60 ml/min per 1.73 m2 and
diabetes or hypertension. These ﬁndings may be
explained by the relatively young mean age of the pa-
tients in this cohort and thus the relatively short follow-
up period of the study. Nonetheless, we found that
diabetes and hypertension were both independently
associated with an increased HR for albuminuria. In
addition, the low baseline prevalence of AIDS (13.7%)
and early HIV diagnoses may explain the surprising
observation that the risk of CKD was decreased in pa-
tients with a high viral load compared with those with a
low viral load. AIDS status did not seem to be a risk
factor for an eGFR <60 ml/min per 1.73 m2 but was
strongly associated with the development of albumin-
uria, a key feature of HIV-associated nephropathy.41
We also observed an association between an
eGFR <60 ml/min per 1.73 m2 and ethnicity, as patients
of sub-Saharan descent had a reduced HR for the
development of CKD compared with other groups. This
was likely related to the use of the race factor for eGFR
estimation, as this association was not signiﬁcant in a
sensitivity analysis excluding its use and adjusting for
age in the equation. Indeed, eGFR formulas corrected
for ethnicity may overestimate the renal function in
African Europeans.42
Our study had some limitations. First, our ﬁndings
are based on observational data, which may weaken
the assessment of causal relationships between risk
factors and outcome. Therefore, the study cannot
distinguish between LD itself or a risk factor for LD
(e.g., long-term use of early nucleoside reverse tran-
scriptase inhibitors) as the causal link to CKD. How-
ever, our aim was to determine whether the presence
of clinical LD should lead to a higher suspicion of CKD
independent of factors that causally link the 2 events.
In addition, LD was diagnosed clinically, as currently
recommended, rather than by body composition
measurements, given that radiologic methods are not
well standardized and are cumbersome to perform at
the population level. Although the deﬁnition of LD
used herein is not standardized, it is similar to that
used in routine clinical practice. Clinician assessment
exhibits substantial agreement with a more compre-
hensive assessment of LD (k ¼ 0.65; P < 0.001) and
has been used previously in several studies.20,43 To
decrease the risk of misclassiﬁcation with respect to
the diagnosis of LD, we diagnosed LD only in patients
with 2 consecutive LD diagnoses within a 6-month
period.
Second, albuminuria was measured by dipstick
testing, and the coding for the diagnosis of this semi-
quantitative variable (, þ, þþ, and þþþ) may have
prevented a standardization among the 7 SHCS centers.
In addition, GFR was estimated using the CKD-EPI
formula derived from creatinine. This equation is
used to estimate renal function in patients with HIV.44
However, the accuracy of the CKD-EPI formula is still
lower than that used for other populations.
In conclusion, to our knowledge this is the ﬁrst
report demonstrating that clinically diagnosed LD is
associated with CKD independently of known risk
factors in a large prospective nationwide cohort study.
Our ﬁndings suggest that HIV-positive patients with
LD should be monitored more closely with respect to
renal function. In addition, exposure to nephrotoxic
ARTs (e.g., TDF) should be minimized in these patients.
Additional works exploring the pathophysiology of
this clear association are needed.
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SUPPLEMENTARY MATERIAL
Table S1. Distribution of GFR stage at baseline and the last
follow-up visit based on the presence of LD. 1Comparison
of GFR category proportions between patients with and
without LD at the last follow-up visit (chi-squared test 20.1,
P < 0.001). 2Comparison of GFR category proportions
among LD phenotypes at the last follow-up visit (chi-
squared test 49.8, P < 0.001).
Table S2. Alternative multivariable model for the
development of an eGFR <60 ml/min per 1.73 m2. AIDS,
acquired immunodeﬁciency syndrome; ART, antiretroviral
therapy; CI, conﬁdence interval; eGFR, estimated glomerular
ﬁltration rate; HBV, hepatitis B virus; HCV, hepatitis C virus;
HR, hazard ratio; LA, lipoatrophy; LD, lipodystrophy; LH,
lipohypertrophy; NRTI, nucleoside reverse transcriptase
inhibitors; RTV, ritonavir; TDF, tenofovir. Model adjusted for
the variables mentioned. In bold: P < 0.05.
Table S3. Multivariable models for the development of
albuminuria. The model was also adjusted for the center
(global P value <0.001). AIDS, acquired immunodeﬁciency
syndrome; ART, antiretroviral therapy; CI, conﬁdence
interval; eGFR, estimated glomerular ﬁltration rate; HBV,
hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio;
LA, lipoatrophy; LD, lipodystrophy; LH, lipohypertrophy;
NRTI, nucleoside reverse transcriptase inhibitors; RTV,
ritonavir; TDF, tenofovir. In bold: P < 0.05.
Appendix S1. Members of the Swiss HIV Cohort Study
group.
Supplementary information linked to the online version of
the paper at www.kireports.org.
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